We are live on ! Find out more
MLYS icon

Mineralys Therapeutics
MLYS

108 hedge funds and large institutions have $572M invested in Mineralys Therapeutics in 2024 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 44 increasing their positions, 17 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

159% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 17

14% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 14

6% more capital invested

Capital invested by funds: $540M → $572M (+$32.2M)

4.16% more ownership

Funds ownership: 89.25% → 93.4% (+4.2%)

2% more funds holding

Funds holding: 106 → 108 (+2)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

88% less call options, than puts

Call options by funds: $1K | Put options by funds: $8K

Holders
108
Holders Change
+2
Holders Change %
+1.89%
% of All Funds
1.42%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
16
Increased
44
Reduced
17
Closed
14
Calls
$1K
Puts
$8K
Net Calls
-$7K
Net Calls Change
-$50K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$13.1M
2
IHAM
Integral Health Asset Management
New York
+$6.79M
3
JP Morgan Chase
JP Morgan Chase
New York
+$6.3M
4
SC
Stempoint Capital
New York
+$5.23M
5
Jennison Associates
Jennison Associates
New York
+$5.04M

Top Sellers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
-$7.27M
2
ASP
Adams Street Partners
Illinois
-$5.27M
3
O
OrbiMed
New York
-$5.12M
4
BOCH
Blue Owl Capital Holdings
New York
-$2.38M
5
Ensign Peak Advisors
Ensign Peak Advisors
Utah
-$1.51M
Name Holding Trade Value Shares
Change 		Change in
Stake
AAA
26
Affinity Asset Advisors
New York
$4.31M – – –
IC
27
Ikarian Capital
Texas
$4.09M +$1.99M +152,390 +85%
CS
28
Candriam SCA
Luxembourg
$3.76M +$3.99M +305,272 New
Fidelity Investments
29
Fidelity Investments
Massachusetts
$3.74M +$5.57K +426 +0.1%
Northern Trust
30
Northern Trust
Illinois
$3.03M +$22.1K +1,688 +0.7%
Charles Schwab
31
Charles Schwab
California
$2.65M +$17.1K +1,307 +0.6%
SFM
32
Sphera Funds Management
Israel
$2.35M -$1.07M -81,800 -30%
DCM
33
DAFNA Capital Management
California
$1.8M – – –
PFCS
34
Pale Fire Capital SE
Czech Republic
$1.69M – – –
Prudential Financial
35
Prudential Financial
New Jersey
$1.55M +$758K +58,000 +86%
Renaissance Technologies
36
Renaissance Technologies
New York
$1.47M +$205K +15,700 +15%
Goldman Sachs
37
Goldman Sachs
New York
$1.38M +$294K +22,464 +25%
Bank of America
38
Bank of America
North Carolina
$1.33M +$151K +11,549 +12%
PAMP
39
Polar Asset Management Partners
Ontario, Canada
$1.22M +$766K +58,600 +145%
Wellington Management Group
40
Wellington Management Group
Massachusetts
$1.13M +$360K +27,531 +43%
NIM
41
NEOS Investment Management
Connecticut
$1.1M -$444K -33,969 -28%
TE
42
Tema ETFs
New York
$1.1M +$1.17M +89,529 New
LPC
43
Lion Point Capital
New York
$972K – – –
N
44
Nuveen
North Carolina
$836K – – –
Bank of New York Mellon
45
Bank of New York Mellon
New York
$804K +$22.4K +1,711 +3%
UBS Group
46
UBS Group
Switzerland
$602K +$429K +32,785 +204%
Barclays
47
Barclays
United Kingdom
$571K +$107K +8,178 +21%
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$499K +$9.09K +695 +2%
AA
49
ALPS Advisors
Colorado
$495K +$25.9K +1,984 +5%
UOC
50
UBS O'Connor
Illinois
$346K -$39.2K -3,000 -10%
1
2
3 4 5

MLYS Hedge Fund Activity: Q4 2024 in Review

108 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Mineralys Therapeutics (MLYS) for Q4 2024, worth a combined $572M — up 6% from $540M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new MLYS positions and 14 closed out — a net gain of 2 holders — while 44 added to existing stakes and 17 trimmed.

The largest buyer was Millennium Management, adding an estimated $13.1M. The largest seller was Octagon Capital Advisors, exiting entirely with an estimated $7.27M sold.

  • 108 institutional investors held Mineralys Therapeutics (MLYS) as of Q4 2024, up from 106 in Q3 2024.
  • Funds reported $572M of Mineralys Therapeutics stock for Q4 2024, up 6% quarter-over-quarter.
  • 16 funds opened new Mineralys Therapeutics positions in Q4 2024 and 14 closed out, a net change of +2 holders.
  • The largest Mineralys Therapeutics buyer in Q4 2024 was Millennium Management, an estimated $13.1M added.
  • The largest Mineralys Therapeutics seller in Q4 2024 was Octagon Capital Advisors, an estimated $7.27M sold.

Based on aggregated 13F filings for Q4 2024.